Select Region or Location
Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • Other Americas
Europe
  • Austria
  • Belgium
  • Bulgaria
  • Croatia/Hrvatska
  • Cyprus
  • Czech Republic
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovak Republic
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Kingdom
  • Other Europe
Asia Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Korea, Republic of
  • Malaysia
  • New Zealand
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Other Asia Pacific
Africa And Middle East
  • Egypt
  • Israel
  • Other Africa And Middle East
USD
Home Cart Sign in  
Chemical Structure| 50-89-5 Chemical Structure| 50-89-5

Structure of Thymidine
CAS No.: 50-89-5

Chemical Structure| 50-89-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Thymidine, a constituent of DNA, pairs with adenine and attach to the sugar deoxyribose in the DNA double helix.

Synonyms: DThyd; NSC 21548; AI3-52267

4.5 *For Research Use Only! Not for Human Use. We Do Not Sell to Patients.

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]}{[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}
    {[ size_append_text(item.pr_size, proInfo.prAm, 'list') ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Mao, Edna ; Chung, Cheol K ; Ji, Yining ; Lam, Yu-hong ; Maligres, Peter E ;

Abstract: A class of organocatalysts that are highly active for the conversion of 2′-deoxynucleosides to furanoid glycals have been discovered. These phosphorimides, (Ph2PS)2NH and (Ph2PSe)2NH, were shown to effectively mediate persilylation of 2′-deoxynucleosides allowing the elimination of the nucleobase giving the corresponding glycal. These mild conditions were demonstrated in the syntheses of glycals with various substitution patterns while minimizing the formation of undesired byproducts and expanding the scope of this methodology.

Purchased from AmBeed:

Pan, Linyue ; Tan, Yuting ; Wang, Bin ; Qiu, Wenjia ; Yin, Yulei ; Ge, Haiyan , et al.

Abstract: Purpose: Caspase recruitment domain containing protein 9 (CARD9) has been demonstrated to be a pro-tumor factor in various cancers. However, our previous study found a significant decrease of CARD9 in malignant pleural effusion compared with benign pleural effusion. So we investigated the role of CARD9 in non-small cell lung cancer (NSCLC) and its working mechanism. Materials and Methods: Immunohistochemistry, western blot, and quantitative real-time polymerase chain reaction were used to detect the expression of CARD9 in specimens of NSCLC patients. The Cancer Genome Atlas (TCGA) databasewas also used to analyze the expression of CARD9 in NSCLC and its predicting value for prognosis. Immunofluorescence was used for CARD9 cellular location. Cell growth assay, clonal formation assay, wound healing assay, matrigel invasion assay, and flow cytometry were used to test cell proliferation, migration, invasion, apoptosis, and cycle progression of NSCLC cells with CARD9 knockdown or CARD9 overexpression. Co-immunoprecipitation was used to identify the interaction between CARD9 and B-cell lymphoma 10 (BCL10). SB203580 was used to inhibit p38 activation. Results: CARD9 was decreased in NSCLC tissues compared with normal tissues; low CARD9 expression was associated with poor survival. CARD9 was expressed both in tumor cells and macrophages. Downregulation of CARD9 in NSCLC cells enhanced the abilities of proliferation, invasion and migration via activated MAPK/p38 signaling, while overexpression of CARD9 presented antitumor effects. BCL10 was identified to interact with CARD9. Conclusion: We demonstrate that CARD9 is an independent prognostic factor in NSCLC patients and inhibits proliferation, migration, and invasion by suppressing MAPK/p38 pathway in NSCLC cells.

Keywords: CARD9 ; Non-small cell lung cancer ; Prognosis ; Targeted therapy

Purchased from AmBeed:

Alternative Products

Product Details of Thymidine

CAS No. :50-89-5
Formula : C10H14N2O5
M.W : 242.23
SMILES Code : O=C1NC(C(C)=CN1[C@@H]2O[C@H](CO)[C@@H](O)C2)=O
Synonyms :
DThyd; NSC 21548; AI3-52267
English Name :1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
MDL No. :MFCD00006537
InChI Key :IQFYYKKMVGJFEH-XLPZGREQSA-N
Pubchem ID :5789

Safety of Thymidine

Related Pathways of Thymidine

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A431, A549, HSC3 cancer cell lines 25 μM To validate the proliferation capacity of TYMS−/− cancer cell lines under thymidine supplementation, results showed that TYMS−/− cancer cell lines proliferated comparably to TYMS+/+ when supplemented with 25 μM dTMP. Mol Ther. 2024 Aug 7;32(8):2535-2548.
HEL24.3 hiPSCs 20 μM 6 days To validate the proliferation capacity of TYMS−/− hiPSCs under thymidine supplementation, results showed that TYMS−/− hiPSCs proliferated comparably to TYMS+/+ when supplemented with 20 μM dTMP. Mol Ther. 2024 Aug 7;32(8):2535-2548.
B16 cells 6 μM 72-96 hours To evaluate the rescue effect of thymidine on ATR inhibitor-induced B16 cell death. Thymidine partially rescued ATR inhibitor-induced cell death. Cell Rep. 2022 Sep 20;40(12):111371.
CT26 cells 6 μM 72 hours To evaluate the rescue effect of thymidine on ATR inhibitor-induced CT26 cell death. Thymidine partially rescued ATR inhibitor-induced cell death. Cell Rep. 2022 Sep 20;40(12):111371.
CD8+ T cells 6 μM 24 hours To evaluate the rescue effect of thymidine on ATR inhibitor-induced CD8+ T cell death. Thymidine partially rescued ATR inhibitor-induced cell death. Cell Rep. 2022 Sep 20;40(12):111371.
CEM dCKlow cells 50 µM 24 hours After dCK knockdown, dT-induced dCTP pool recovery was impaired, leading to stalled DNA replication, replication stress, and apoptosis J Exp Med. 2014 Mar 10;211(3):473-86.
CCRF-CEM (CEM) human T-ALL cells 50 µM 24 hours dT increased dTTP and decreased dCTP, leading to S-phase arrest; dC supplementation prevented S-phase arrest J Exp Med. 2014 Mar 10;211(3):473-86.
Primary murine bone marrow derived macrophages (pBMDMs) 5 μg/mL 4 hours To assess the impact of ΔthyA mutation on c-di-AMP production and STING activation. Results showed that ΔthyA mutation significantly increased c-di-AMP levels and Ifnb1 expression. Cell Host Microbe. 2022 Jul 13;30(7):961-974.e6.
Human fibroblasts 100 μM 30 days Thymidine combined with FGF2 induced the conversion of human fibroblasts to iNeus. Cell Mol Immunol. 2022 May;19(5):619-633.
Mouse embryonic fibroblasts (MEFs) 100 μM 15 days Thymidine induced the conversion of MEFs to neutrophils (iNeus) with antibacterial functions. Cell Mol Immunol. 2022 May;19(5):619-633.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice NSG mice Drinking water 100 and 250 mg/kg/day Continued for 6-8 weeks To validate the teratoma formation capacity of TYMS?/? hiPSCs in vivo, results showed that TYMS?/? hiPSCs formed teratomas only under 100 and 250 mg/kg/day dTMP supplementation, while almost no teratomas formed without supplementation. Mol Ther. 2024 Aug 7;32(8):2535-2548.
NSG mice Subcutaneous CEM dCKwt and dCKlow xenograft models Intraperitoneal injection 2 g/kg Every 12 hours for 6 days DT treatment blocked growth of dCKlow tumors but not dCKwt xenografts; DI-39/dT combination therapy significantly reduced tumor burden J Exp Med. 2014 Mar 10;211(3):473-86.
Mouse Curly tail mouse model Intraperitoneal injection 2 mg/ml Daily from embryonic Day 7.5 to Day 10.5 To test the protective effect of nucleotide precursors on neural tube defects, results showed that thymidine combined with adenine or GMP significantly reduced the incidence of spina bifida Brain. 2013 Sep;136(Pt 9):2836-41

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.13mL

0.83mL

0.41mL

20.64mL

4.13mL

2.06mL

41.28mL

8.26mL

4.13mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories